arrow
A

Alan W. Heldman

university of miami
H指数:40
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study)
2017-11-10153
OAAI
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, PlaceboControlled Clinical Trial
2017-07-17128
OAAI
Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty
2017-04-2179
OAAI
Does Transendocardial Injection of Mesenchymal Stem Cells Improve Myocardial Function Locally or Globally? An Analysis From the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis ( POSEIDON) Randomized Trial
2014-04-1199
OAAI
Autologous Mesenchymal Stem Cells Produce Concordant Improvements in Regional Function, Tissue Perfusion, and Fibrotic Burden When Administered to Patients Undergoing Coronary Artery Bypass Grafting
2014-04-11292
OAAI
Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy The TAC-HFT Randomized Trial

经心内膜间充质干细胞和骨髓单个核细胞治疗缺血性心肌病的tac-hft随机试验

2014-01-01465
OAAI
Comparison of Allogeneic vs Autologous Bone Marrow-Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy The POSEIDON Randomized Trial
2012-12-121.0K
OAAI
Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy
2011-03-01131
PREAI